High-Dose Stereotactic Radiation for Prostate Cancer

Inclusion Criteria: * The patient must have prostate adenocarcinoma proven by histologic diagnosis * The patient must have clinical stage T1a-T3b with localized prostate cancer considered low, intermediate, or high risk as defined by the National Comprehensive Cancer Network (NCCN) guidelines; any patient whom is defined as high-risk must undergo screening with computed tomography (CT) or magnetic resonance imaging (MRI) of the abdomen and pelvis as well as bone scan prior to enrollment for staging purposes; low and intermediate risk patients do not require imaging for staging unless they have a focal symptom warranting investigation * Performance status - Karnofsky performance status (PS) \>= 70 * Life expectancy of \> 5 years, in the opinion of and as documented by the investigator * Patients must either already have fiducials already placed within the prostate, or otherwise be candidates for prostate fiducial placement (no bleeding disorders which may cause excessive bleeding with fiducial placement, INR \< 2.0). * Patients must have prostate-specific antigen (PSA) drawn within the 90 days prior to enrollment * Men must agree to use adequate contraception (double barrier method of birth control or abstinence) for the duration of study participation and for 12 months after completing treatment * Subjects must have the ability to understand and the willingness to sign a written informed consent document Exclusion Criteria: * Prior treatment toxicities must be resolved to …